Tropic
London, UK· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A synthetic biology firm using CRISPR to engineer microbes for sustainable manufacturing and therapeutic production.
Industrial Biotechnology
Technology Platform
A CRISPR-based gene editing platform for the rapid design and optimization of microbial production strains for biosynthesis.
Opportunities
Potential to disrupt traditional chemical manufacturing and biologics production through more efficient and sustainable biological processes.
Risk Factors
High technical and scaling challenges, alongside significant competition in the platform synthetic biology sector.
Competitive Landscape
Faces competition from larger, well-funded synthetic biology companies like Ginkgo Bioworks and Zymergen in the industrial bioengineering space.